Medicare Part B ASP Cost Savings Fall Below Government Expectations, Lawyer Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Congress is considering methods to improve cost savings from Part B reimbursement, Sidley Austin attorney says at International Pharmaceutical Compliance Summit in Philadelphia. Analysts note that the full impact of the average sales price-based Part B reimbursement is not yet evident.
You may also be interested in...
CMS Expects No Significant Change In Average Sales Prices Before 2005
The agency’s final 2005 Physician Fee Schedule includes a second round of preliminary ASPs, with data for a larger number of drugs than in the proposed rule. Final average sales prices for the first quarter of 2005 will be published in December.
NDAs Should Include More Cross-Study Analysis, FDA Says In Draft Guidance
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications
New Look At Ezetimibe Fails To Confirm Vytorin Cancer Signal
Interim data from SHARP and IMPROVE-IT trials fail to show evidence of impact on cancer rates.